Quince Therapeutics, Inc. (QNCX) Stock

Quince Therapeutics, Inc. (QNCX) is a Healthcare stock trading at $0.93 (as of 2026-06-18), with a market capitalization of $9.08M and a trailing P/E of 0.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Quince Therapeutics, Inc. is a biopharmaceutical company developing precision therapeutics for debilitating and rare diseases using a bone-targeting platform designed to deliver small molecules, peptides, or large molecules to the site of bone fracture and disease. Its lead candidate, NOV004, is an anabolic peptide engineered to concentrate at bone fracture sites.

Valuation — source: SEC EDGAR (first-party)
Price	$0.93
Market Cap	$9.08M
P/E Ratio	0.7
EV / EBITDA	-0.0
Price / Book	1.20
DCF Value (model)	$-4.44
DCF Upside vs Price	-579.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.24M
Net Margin	-6750.7%
Return on Equity	-210.8%
Current Ratio	2.92
Revenue Growth (YoY)	-60.6%
EPS Growth (YoY)	-1158.8%
FCF Growth (YoY)	-21.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-8.49 (distress)

Valuation vs Sector & Industry
Stock P/E	0.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-96.4%
vs Industry	-95.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Nantahala Capital Management, LLC ($8.95M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dirk Thye
Employees	36
Country	US
IPO Date	2019-05-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.